We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




First-Ever POC Analyzer Reads Patient's Immune System to Detect Diseases Before Symptoms Present

By LabMedica International staff writers
Posted on 19 May 2023

Each year, sepsis affects over 50 million individuals worldwide and accounts for nearly 20% of all fatalities. More...

Additionally, sepsis poses a substantial economic strain, with projected costs exceeding USD 62 billion annually in the U.S. alone. However, rapid diagnosis and treatment could potentially prevent up to 80% of sepsis-related deaths. Now, a breakthrough point-of-care diagnostic platform that leverages the power of the human immune system is poised to address the two main challenges associated with sepsis: broad screening and rapid identification.

Immune Reveal, a first-of-its-kind point-of-care diagnostic platform, is a collaborative creation of Immune IQ (Twin Cities, MN, USA) and Honeywell (Charlotte, NC, USA). This groundbreaking platform integrates automatic disease screening with confirmatory tests to rapidly offer unique insights into various diseases, such as sepsis, heart disease, cancer, and COVID-19. The Immune Reveal platform offers diagnostic information quicker and more cost-effectively than ever before. With one of the most powerful data sets in the industry and the incorporation of artificial intelligence within its system, Immune Reveal could redefine the standard of care in diagnosis and treatment.

Immune Reveal generates one of the industry's most powerful data sets, which, when translated by artificial intelligence, can " read " diseases that a patient's immune system has detected even before the appearance of symptoms. This game-changing approach paves the way for a new era of integrated tests that can perform disease screening, confirmation testing, and precision treatment testing in minutes using the same card and sample. Immune IQ plans to commercialize sepsis detection as the initial test on the Immune Reveal platform. A recent clinical study successfully showcased Immune Reveal's ability to consistently generate a large cellular dataset. The combination of this data has been independently demonstrated in peer-reviewed publications to yield highly accurate sepsis detection.

"The human immune system is widely recognized as a near-perfect tool for detecting disease, even far in advance of noticeable symptoms. Immune Reveal is the first platform that can both read and decode the immune system's data in as soon as five minutes," said Immune IQ founder and CEO, David Deetz.

Related Links:
Immune IQ
Honeywell


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.